75.56
-2.51 (-3.22%)
| 前收盘价格 | 78.07 |
| 收盘价格 | 77.12 |
| 成交量 | 1,009,464 |
| 平均成交量 (3个月) | 688,042 |
| 市值 | 3,905,230,592 |
| 预期市盈率 (P/E Forward) | 39.68 |
| 价格/销量 (P/S) | 8.13 |
| 股市价格/股市净资产 (P/B) | 14.13 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | -20.39% |
| 营业利益率 (TTM) | -13.61% |
| 稀释每股收益 (EPS TTM) | -1.61 |
| 季度收入增长率 (YOY) | 61.20% |
| 总债务/股东权益 (D/E MRQ) | 135.97% |
| 流动比率 (MRQ) | 3.22 |
| 营业现金流 (OCF TTM) | -6.85 M |
| 杠杆自由现金流 (LFCF TTM) | -23.97 M |
| 资产报酬率 (ROA TTM) | -7.11% |
| 股东权益报酬率 (ROE TTM) | -33.06% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Mirum Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.40 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.90% |
| 机构持股比例 | 114.19% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 132.00 (Citizens, 74.70%) | 购买 |
| 中 | 125.00 (65.43%) | |
| 低 | 88.00 (Baird, 16.46%) | 购买 |
| 平均值 | 117.43 (55.41%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 92.34 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citizens | 26 Feb 2026 | 132.00 (74.70%) | 购买 | 105.16 |
| 19 Dec 2025 | 140.00 (85.28%) | 购买 | 77.74 | |
| Stifel | 26 Feb 2026 | 125.00 (65.43%) | 购买 | 105.16 |
| 16 Dec 2025 | 98.00 (29.70%) | 购买 | 67.05 | |
| RBC Capital | 18 Feb 2026 | 130.00 (72.05%) | 购买 | 105.10 |
| Morgan Stanley | 30 Jan 2026 | 123.00 (62.78%) | 购买 | 103.22 |
| 09 Dec 2025 | 95.00 (25.73%) | 购买 | 65.40 | |
| HC Wainwright & Co. | 26 Jan 2026 | 130.00 (72.05%) | 购买 | 96.92 |
| 13 Jan 2026 | 102.00 (34.99%) | 购买 | 90.44 | |
| Baird | 09 Dec 2025 | 88.00 (16.46%) | 购买 | 65.40 |
| Evercore ISI Group | 09 Dec 2025 | 94.00 (24.40%) | 购买 | 65.40 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| RAMASASTRY SAIRA | - | 103.10 | -2,000 | -206,200 |
| 累积净数量 | -2,000 | |||
| 累积净值 ($) | -206,200 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 103.10 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RAMASASTRY SAIRA | 董事 | 13 Feb 2026 | 自动卖出 (-) | 2,000 | 103.10 | 206,200 |
| RAMASASTRY SAIRA | 董事 | 13 Feb 2026 | 执行期权 | 2,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合